Pardes Biosciences

United States
Johnson, Vermont, United States, 92008

Company profile

Pardes Biosciences company profile

Pardes Biosciences is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines. The company’s lead product candidate, PBI-0451, is being developed as a direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, the virus responsible for COVID-19. Pardes Biosciences is on a mission to stop a pandemic and start a movement so patients everywhere can get well sooner.

Business identity

Phone number
415-649-8758
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2020-01-01, Year

Headquarters

Postal code
92008
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
3
Total equity funding
$126.6M
Last funding
Post IPO Equity / $75M / 2021-12-27
Last equity funding
Post IPO Equity / $75M
Investors
11
Lead investors
1
Founders
1
Articles
30
Exited on
2021-12-27

Founders and investors

Founders

Uri Lopatin

Lead investors

Foresite Capital

Investors

Foresite CapitalLiquid 2 VenturesRA Capital ManagementT. Rowe PriceY Combinator